Perspective - Journal of Diabetes Medication & Care (2025) Volume 8, Issue 3
Geriatric Diabetes Pharmacology: Tailoring Therapy for Older Adults
Dr. Maria Rossi*
Dept. of Geriatric Medicine, University of Verona Health, Italy
- *Corresponding Author:
- Dr. Maria Rossi
Dept. of Geriatric Medicine, University of Verona Health, Italy
E-mail: maria.rossi@uvh.it
Received: 01-Jun-2025, Manuscript No. jdmc-26-184891; Editor assigned: 03- Jun -2025, PreQC No. jdmc-26-184891 (PQ); Reviewed: 18- Jun -2025, QC No. jdmc-26-184891; Revised: 21- Jun -2025, Manuscript No. jdmc-26-184891 (R); Published: 30- Jun -2025, DOI: 10.37532/JDMC.2025.7(3). 293
Introduction
Managing diabetes in older adults presents unique challenges due to age-related physiological changes, comorbidities, and increased susceptibility to adverse drug effects. Pharmacologic therapy in this population requires careful consideration of renal and hepatic function, cardiovascular status, cognitive ability, and polypharmacy [1,2]. Geriatric diabetes pharmacology aims to optimize glycemic control while minimizing risks such as hypoglycemia, falls, and medication interactions, emphasizing individualized, safe, and effective treatment strategies.
Discussion
Older adults often exhibit altered pharmacokinetics and pharmacodynamics. Reduced renal clearance and hepatic metabolism can increase drug exposure and toxicity, necessitating dose adjustments for medications such as metformin, sulfonylureas, and certain insulin formulations. Age-related changes in gastric absorption, body composition, and protein binding further influence drug distribution and efficacy [3-5].
Hypoglycemia is a particular concern in the geriatric population. Insulin and sulfonylureas carry the highest risk, especially in patients with irregular meal patterns, renal impairment, or cognitive decline. Therefore, newer agents such as DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors are often preferred due to their lower hypoglycemia risk and additional benefits, including weight management and cardiovascular protection.
Polypharmacy is common among older adults, increasing the potential for drug-drug interactions and complicating adherence. Fixed-dose combination medications, simplified dosing schedules, and long-acting formulations can reduce pill burden and improve compliance. Clinicians must carefully balance glycemic targets with overall health goals, considering life expectancy, frailty, and quality of life. Less stringent targets may be appropriate in patients with limited functional reserve or multiple comorbidities.
Patient-centered education and engagement are essential. Older adults may require additional support with medication administration, understanding dosing schedules, and recognizing signs of hypo- or hyperglycemia. Regular monitoring, including laboratory tests and clinical assessment, enables timely adjustment of therapy in response to changes in health status or renal function.
Conclusion
Geriatric diabetes pharmacology emphasizes individualized therapy that balances efficacy, safety, and quality of life. By accounting for age-related physiological changes, comorbidities, and polypharmacy, clinicians can minimize adverse effects while achieving meaningful glycemic control. Personalized drug selection, dose adjustments, and patient education are essential to optimize outcomes in older adults with diabetes. As the population ages, tailored pharmacologic strategies will continue to play a pivotal role in improving the health and well-being of this vulnerable group.
References
- Von-Seidlein L, Kim DR, Ali M, Lee HH, Wang X, Thiem VD, et al. (2006) A multicentre study of Shigella diarrhoea in six Asian countries: Disease burden, clinical manifestations, and microbiology. PLoS Med 3: e353.
- Germani Y, Sansonetti PJ (2006) The genus Shigella. The prokaryotes In: Proteobacteria: Gamma Subclass Berlin: Springer 6: 99-122.
- Aggarwal P, Uppal B, Ghosh R, Krishna Prakash S, Chakravarti A, et al. (2016) Multi drug resistance and extended spectrum beta lactamases in clinical isolates of Shigella: a study from New Delhi, India. Travel Med Infect Dis 14: 407â413.
- Taneja N, Mewara A (2016) Shigellosis: epidemiology in India. Indian J Med Res 143: 565-576.
- Farshad S, Sheikhi R, Japoni A, Basiri E, Alborzi A (2006) Characterization of Shigella strains in Iran by plasmid profile analysis and PCR amplification of ipa genes. J Clin Microbiol 44: 2879â2883.
